Probenecid has been widely used in the treatment of gout, but evidence suggest that it may also have anti-nociceptive effects in different inflammatory and pain conditions. We examined the potential modulatory effects of probenecid on behavioural and morphological markers in the orofacial formalin test of the rat.
Introduction
Probenecid (PROB, p-(di-n-propylsulfamyl)benzoic acid) has primarily been used to enhance the renal retention of penicillin and to treat gout, due to its ability to increase the renal excretion of uric acid . Besides its effects on the kidney, research data suggest that PROB may have anti-inflammatory and anti-nociceptive properties as well. PROB blocks the multidrug resistance-associated protein 4 (MRP4), an organic anion transporter , which is crucial in the release of key inflammatory mediators such as prostaglandin E1 and prostaglandin E2 (PGE2) . In addition, PROB inhibits the pannexin-1 channel , which may be relevant in neuronal inflammatory processes . On the other hand, PROB is an agonist of the transient receptor potential channel subtype A member 1 (TRPA1) and the transient receptor Based on previous experimental results, it has been proposed that PROB, through its different receptorial actions, may have anti-nociceptive effect that can be seen in the orofacial formalin test. Thus the aim of the current study was to investigate whether PROB exerts a modulatory effect in this tonic trigeminal pain model through the examination of behavioural and morphological markers.
Materials and Methods

Animals:
The procedures used in this study followed the guidelines of the eighth edition of the Guide dark-light cycle. Each rat was used only once.
Drug administration:
The rats were divided into two groups (n=30 per group). The animals in the Placebo group received only intraperitoneal vehicle solution (physiological saline, 1.5 ml) as pre-treatment.
In the PROB group, the rats were pretreated with an intraperitoneal injection of PROB (Sigma-Aldrich; 1 mmol/kg body weight, diluted to 1.5 ml, pH 7.4). Both groups of animals were divided further into two subgroups (n=15): 1 hour after the PROB or vehicle pretreatment, half of the animals received a s.c. injection of 50 µl 1.5% formalin solution (0.55% formaldehyde, Sigma-Aldrich) diluted in physiological saline, administered via a 26-gauge needle into the right whisker pad (Placebo-Form and PROB-Form), while the other half of the rats were injected with s.c. 50 µl physiological saline without formalin (Placebo-Phys and PROB-Phys).
Behavioural test:
The testing procedures were performed during the light phase (between 8 a.m. and 2 p.m.) in a quiet room. The test box was a 30 x 30 x 30 cm glass terrarium with mirrored walls. For the off-line analysis of rubbing activity directed to the whisker pad, the behaviour of the individually tested rats was recorded with a video camera (Logitech HD Webcam C615) situated 1 m above the terrarium. One hour after pre-treatment with vehicle (n=20) or PROB (n=20) and after a 10-min habituation in the test box, the whisker pads of the rats were injected with s.c. formalin (n=10 per subgroup) or physiological saline (n=10 per subgroup) and the animals were replaced immediately back in the chamber for 45 min. The rats did not receive any food or water during the observation period. The test box was cleaned and decontaminated after each animal. An observer blind to the experimental procedures analysed the recorded videos. The 45-min recording period was divided into 15x3-min blocks and the total time (number of seconds) spent on rubbing the injected area with the ipsilateral fore-or hindpaw was measured in each block and defined as the nociceptive score for that block. Earlier literature findings led us to use the grooming activity as control, measured in animals that received s.c. physiological saline .
c-Fos and nNOS immunohistochemistry:
Four hours after the formalin or physiological saline injection, the rats (n=5-9 per subgroup) were perfused transcardially with 100 ml phosphate-buffered saline (PBS), 
Statistical analysis:
In the behavioural study, comparisons were made of the rubbing activity in each block of 3-min in each of the subgroups (Placebo-Form, Placebo-Phys, PROB-Form and PROB-Phys) by using two-way repeated measures ANOVA. Subgroups were used as the between-subject factor and 15 blocks of 3-min as the within-subject factor for the analysis. When Mauchly's test of sphericity proved significant, the Greenhouse-Geisser correction was performed.
Pairwise comparisons of subgroup means were based on the estimated marginal means with Sidak adjustment for multiple comparisons.
To compare statistical differences between subgroups in the first and second phases, the two phases were determined on the basis of significant results detected during two-way repeated measures ANOVA described above. The first phase was found to be the first of the 15 blocks, while the second phase was the sum of the fifth to the eleventh blocks. To determine significant differences between subgroups in the first or second phase, we used one-way ANOVA followed by the Tamhane post hoc test.
In terms of the immunoreactivity, the numbers of IR neurones in the various subgroups All tests were two-sided, and probability levels p<0.05 were considered to be statistically significant. Group values are reported as means ± S.E.M.
Statistical analysis of measurements was carried out with IBM SPSS Statistics, version 20 (IBM Corporation) software.
Results
Nociceptive response
The behavioural pattern observed in the rats is in accordance with previous findings .
After the formalin injection, the rats immediately withdrew their heads, often accompanied by vocalization. Following their return to the observation box, the rats started to rub their whisker pad continuously and intensely with the ipsilateral forepaw accompanied often by the contralateral forepaw, and occasionally scraped the perinasal area with the ipsilateral hindpaw after a period of ~20 sec. This period, referred to as the first phase, lasted ~3-4 min, and was followed by a quiescent period of 9-10 min, separating the first phase from the second phase. The second phase was characterized by less intense, but continuous rubbing of the face, predominantly with the ipsilateral forepaw consorted often by the contralateral forepaw as well. This tonic phase lasted ~20-22 min. In the PROB-Form subgroup, the behavioural pattern in both phases was clearly less pronounced than that in the Placebo-Form subgroup, and such behaviour was not witnessed at all in the Placebo-Phys and PROB-Phys subgroups, where the animals displayed very little rubbing/grooming activity.
The comparison of the 3-min blocks revealed significant differences in rubbing activity between the Placebo-Form and Placebo-Phys subgroups in the first (***p < 0.001) and fifth to eleventh (**p < 0.01; ***p < 0.001) blocks (Fig. 1) . The PROB pre-treatment significantly decreased the formalin-induced nociceptive behaviour in each block ( # # p < 0.01; # # # p < 0.001; Fig. 1 ). However, it should be noted that PROB did not attenuate the effect of formalin completely in the first block, where the time spent on rubbing was still significantly higher than that in the Placebo-Phys subgroup (*p < 0.05; Fig. 1 ). There was no significant difference between the Placebo-Phys and PROB-Phys animals in any block, nor was between the PROB-Form and PROB-Phys subgroups in any other block apart from the first (Fig. 1). 14 The face rubbing activity in the Placebo-Form subgroup was significantly higher during both the first (***p < 0.001) and the second phase (***p < 0.001) than that in the PlaceboPhys subgroup (Fig. 2) . PROB significantly decreased the nociceptive behaviour in both phases (**p < 0.01; ***p < 0.001; Fig. 2 ), however this effect was not complete in the first phase (*p < 0.05; Fig. 2 ).
c-Fos in the TNC
Microscopic examination of the immunostained transverse sections of the TNC revealed c-Fos immunoreactivity in the nuclei of the neurones. In the Placebo-Form subgroup, unilateral s.c. formalin injection produced an increase in the number of c-Fos-IR neurones in the dorsal, superficial area of the transverse sections of the ipsilateral TNC as compared with the non-treated contralateral side (Fig. 3/A) . This increase was significant at different levels along the rostrocaudal axis (between -0.3 and -3.3 mm), in accordance with the somatotopic representation (**p < 0.01; ***p < 0.001; Fig. 3/C) .
In the PROB-Form subgroup, the number of c-Fos-IR neurones at the different levels along the rostrocaudal axis also increased in the ipsilateral TNC. This effect was similar, but less pronounced than that in the Placebo-Form subgroup (Fig. 3/B On the contralateral sides of the TNCs, there were no significant differences either between the subgroups or between the different levels along the rostrocaudal axis (Fig. 3) .
nNOS in the TNC
On the immunostained transverse sections, the nNOS-IR neurones showed cytoplasmic and dendritic staining. The unilateral s.c. formalin injection gave rise to an increase in the number of nNOS-IR neurones in the dorsal, superficial area of the ipsilateral TNC compared to the non-treated contralateral side in the Placebo-Form subgroup (Fig. 4/A) . Along the rostrocaudal axis, significant increase can be observed at different levels (between -2.1 and -2.7 and between -3.3 and -3.9 mm; *p < 0.05; **p < 0.01; Fig. 4/C) . In the PROB-Form subgroup, there was no difference in the number of nNOS-IR neurones between ipsilateral and contralateral TNC (Fig. 4/B (Fig. 4) . It is important to note that some data suggest that PROB is able to activate some of the transient receptor potential channels, including TRPV2 and TRPA1 which play an important role in pain perception and are present in the trigeminal system . However, the agonist-mediated desensitization of these receptors is also known , which can cause an anti-nociceptive effect . PROB can desensitize the TRPA1 and may act similarly on induced a significant increase in rubbing activity in both the first and the second phase (***p < 0.001) as compared with that in the saline-treated animals (Placebo-Phys). In both phases, pre-treatment with PROB had a significant effect on mitigating the formalininduced increase in the time spent in rubbing (**p < 0.01; ***p < 0.001) as compared with the Placebo-Form subgroup. 
IL-1β and NQO1 in the TNC
